{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:59:06Z","timestamp":1791446346979,"version":"4.3.3"},"reference-count":102,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.eplepsyres.2013.08.016","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T22:32:52Z","timestamp":1378247572000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Metabolic and endocrine effects of valproic acid chronic treatment"],"prefix":"10.1016","volume":"107","author":[{"given":"Vincenzo","family":"Belcastro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"D\u2019Egidio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.pediatrneurol.2009.06.003","article-title":"Metabolic alterations during valproic acid treatment: a prospective study","volume":"41","author":"Abaci","year":"2009","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome \u2013 a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet. Med."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0015","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00666.x","article-title":"Role of valproate across the ages. Treatment of epilepsy in children","volume":"184","author":"Aldenkamp","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0025","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1528-1157.1984.tb03480.x","article-title":"Heart disease mortality and morbidity in patients with epilepsy","volume":"25","author":"Annegers","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/07853899709002451","article-title":"Differences in lipolysis between human subcutaneous and omental adipose tissue","volume":"27","author":"Arner","year":"1995","journal-title":"Ann. Med."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eplepsyres.2006.06.015","article-title":"Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy","volume":"71","author":"Attilakos","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0040","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/08830738050200101501","article-title":"Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate","volume":"20","author":"Aydin","year":"2005","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0045","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1528-1167.2007.01164.x","article-title":"Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients","volume":"48","author":"Belcastro","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1528-1167.2009.02303.x","article-title":"Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs","volume":"51","author":"Belcastro","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2012.07.003","article-title":"Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy","volume":"102","author":"Belcastro","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0060","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study","volume":"338","author":"Berenson","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/08830738030180021701","article-title":"Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial","volume":"18","author":"Biton","year":"2003","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0070","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/0026-0495(92)90061-E","article-title":"Metabolic changes during treatment with valproate in humans: implication for untoward weight gain","volume":"41","author":"Breum","year":"1992","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000113927","article-title":"Valproic acid and CEBPalpha-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes","volume":"88","author":"Brown","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0085","first-page":"385","article-title":"On the propyl derivatives and decomposition products of ethylacetoacetate","volume":"3","author":"Burton","year":"1882","journal-title":"Am. Chem. J."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1755-5949.2011.00240.x","article-title":"Metabolic syndrome and bipolar disorder: what should psychiatrists know?","volume":"18","author":"de Almeida","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0105","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1528-1167.2006.00953.x","article-title":"Endocrine effects of valproate in adolescent girls with epilepsy","volume":"48","author":"de Vries","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0887-8994(00)00133-8","article-title":"Weight gain associated with valproate in childhood","volume":"22","author":"Demir","year":"2000","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0887-8994(00)00175-2","article-title":"Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children","volume":"23","author":"Demircioglu","year":"2000","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0130","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1212\/WNL.45.6.1155","article-title":"Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy","volume":"45","author":"Eir\u00ecs","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.eplepsyres.2007.07.005","article-title":"Cardiovascular risk factors and homocysteine in epilepsy","volume":"76","author":"Elliott","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0140","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.0013-9580.2004.66303.x","article-title":"Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy","volume":"45","author":"El-Khayat","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0145","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.seizure.2006.12.009","article-title":"Valproate, weight gain and carbohydrate craving: a gender study","volume":"16","author":"El-Khatib","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.braindev.2008.11.001","article-title":"Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid","volume":"31","author":"Erdemir","year":"2009","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diabetes.52.1.1","article-title":"Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?","volume":"52","author":"Evans","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0160","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.seizure.2012.06.001","article-title":"Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate","volume":"21","author":"Fang","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.ijo.0803453","article-title":"Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention","volume":"31","author":"Fu","year":"2007","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0170","first-page":"122","article-title":"Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy","volume":"102","author":"Geda","year":"2002","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0175","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1212\/01.wnl.0000187074.27586.d1","article-title":"Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid","volume":"65","author":"Greco","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1345\/aph.1L414","article-title":"Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy","volume":"43","author":"Grosso","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0185","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/0883073807307096","article-title":"The role of ghrelin in weight gain and growth in epileptic children using valproate","volume":"22","author":"Gungor","year":"2007","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1254\/jphs.CRJ05003X","article-title":"The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins","volume":"98","author":"Hamed","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0195","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eplepsyres.2007.03.010","article-title":"Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy","volume":"74","author":"Hamed","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejpn.2008.05.005","article-title":"States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain","volume":"13","author":"Hamed","year":"2009","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0205","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/brain\/awh023","article-title":"Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction","volume":"127","author":"Hassan","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0210","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.0013-9580.2004.17504.x","article-title":"The epidemiology of the comorbidity of epilepsy in the general population","volume":"45","author":"Gaitatzis","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0220","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ana.410390506","article-title":"Obesity and endocrine disorders in women taking valproate for epilepsy","volume":"39","author":"Isoj\u00e4rvi","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0225","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","article-title":"Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy","volume":"22","author":"Johannessen Landmark","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0235","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.seizure.2012.05.001","article-title":"Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy","volume":"21","author":"Kanemura","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0240","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0387-7604(02)00163-8","article-title":"Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid","volume":"25","author":"Karabiber","year":"2003","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0245","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/01.STR.14.4.525","article-title":"Increase of low serum concentrations of high-density lipoprotein (HDL) cholesterol in TIA-patients treated with phenytoin","volume":"14","author":"Kaste","year":"1983","journal-title":"Stroke"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0250","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4065\/80.2.219","article-title":"Conditional risk factors for atherosclerosis","volume":"80","author":"Kullo","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0255","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s10571-007-9201-x","article-title":"Valproic acid alters GnRH-GABA interactions in cycling female rats","volume":"27","author":"Lakhanpal","year":"2007","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0260","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0265","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/diacare.19.4.390","article-title":"Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state","volume":"19","author":"Lewis","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0270","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1467-789X.2005.00159.x","article-title":"Adiponectin: action, regulation and association to insulin sensitivity","volume":"6","author":"Lihn","year":"2005","journal-title":"Obes. Rev."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0275","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"Lopinto-Khoury","year":"2010","journal-title":"Curr. Treat. Options Neurol."},{"issue":"48","key":"10.1016\/j.eplepsyres.2013.08.016_bib0280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(01)00317-5","article-title":"Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross-sectional study of women with epilepsy treated with valproate","volume":"2","author":"Luef","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0285","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1053\/meta.2002.34708","article-title":"Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy","volume":"51","author":"Luef","year":"2002","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0295","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.20074","article-title":"Valproate therapy and non-alcoholic fatty liver disease","volume":"55","author":"Luef","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eplepsyres.2009.04.004","article-title":"Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment","volume":"86","author":"Luef","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0305","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0310","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0166-2236(03)00032-8","article-title":"Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders","volume":"26","author":"Mattson","year":"2003","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/diabetes.51.1.7","article-title":"Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes","volume":"51","author":"McGarry","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0320","first-page":"435","article-title":"Pharmacodynamic properties of ndipropylacetic acid","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0325","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1528-1167.2005.34304.x","article-title":"Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation","volume":"46","author":"Mikkonen","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0330","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2009.02235.x","article-title":"Should enzyme-inducing antiepileptic drugs be considered first-line agents?","volume":"50","author":"Mintzer","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0340","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0345","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nn1454","article-title":"Molecular and anatomical determinants of central leptin resistance","volume":"8","author":"M\u00fcnzberg","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0350","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/bmj.291.6507.1481","article-title":"Mortality from ischemic heart disease among the patients using anticonvulsant drugs. A case control study","volume":"291","author":"Muuronen","year":"1985","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0355","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1358\/dot.2005.41.8.893630","article-title":"Drug-induced weight gain","volume":"41","author":"Ness-Abramof","year":"2005","journal-title":"Drugs Today"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0360","first-page":"50","article-title":"The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglycerid elevels in adult epileptic patients on monotherapy","volume":"10","author":"Nikolaos","year":"2004","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0365","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/088307389901400802","article-title":"Risk of excessive weight gain in epileptic children treated with valproate","volume":"14","author":"Novak","year":"1999","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0370","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/pds.2073","article-title":"Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study","volume":"20","author":"Olesen","year":"2011","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0375","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/01.ATV.12.11.1336","article-title":"Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state","volume":"12","author":"Patsch","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0380","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1012592","article-title":"Carotid-wall intima-media thickness and cardiovascular events","volume":"365","author":"Polak","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0385","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0390","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1528-1167.2007.01100.x","article-title":"Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study","volume":"48","author":"Prabhakar","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0395","article-title":"Comparison of two classifications of metabolic syndrome in the pediatric population and the impact of cholesterol","author":"Prodam","year":"2012","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0400","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1046\/j.1528-1157.2002.31501.x","article-title":"Serum insulin and leptin levels in valproate-associated obesity","volume":"43","author":"Pylv\u00e4nen","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0405","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/01.WNL.0000048209.07526.86","article-title":"Fasting serum insulin and lipid levels in men with epilepsy","volume":"60","author":"Pylv\u00e4nen","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0410","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.yebeh.2006.02.008","article-title":"Insulin-related metabolic changes during treatment with valproate in patients with epilepsy","volume":"8","author":"Pylv\u00e4nen","year":"2006","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0415","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1210\/en.2005-1030","article-title":"Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid","volume":"147","author":"Qiao","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0420","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1542\/peds.103.3.588","article-title":"The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy","volume":"103","author":"R\u00e4tty\u00e4","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0425","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.seizure.2008.03.002","article-title":"Adiponectin receptor R1 is upregulated by valproic acid but not by topiramate in human hepatoma cell line, HepG2","volume":"17","author":"Rauchenzauner","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0430","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eplepsyres.2008.03.017","article-title":"Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children","volume":"80","author":"Rauchenzauner","year":"2008","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0435","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1528-1167.2007.01460.x","article-title":"Adiponectin and visfatin concentrations in children treated with valproic acid","volume":"49","author":"Rauchenzauner","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0440","article-title":"The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: Just a sidestep?","author":"Rauchenzaunera","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0445","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/0883073808323023","article-title":"Weight gain in children treated with valproate","volume":"24","author":"Sharpe","year":"2009","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0450","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/08830738060210011301","article-title":"Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes","volume":"21","author":"Sonmez","year":"2006","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0455","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1046\/j.1528-1157.2001.0420081002.x","article-title":"Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy","volume":"42","author":"Sthephen","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0460","first-page":"421","article-title":"Morphological evaluation of steatosis in mono-layer cultures (MDCK cells) after treatment with gentamicin and valproic acid","volume":"4","author":"Stiemer","year":"1989","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0465","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1152\/physrev.00047.2003","article-title":"Role of oxidative modifications in atherosclerosis","volume":"84","author":"Stocker","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0470","first-page":"16","article-title":"Lipoproteins and atherosclerosis in children: an early marriage?","volume":"11","author":"Strong","year":"2001","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0475","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1586\/ern.12.90","article-title":"Treatment of myoclonic seizures","volume":"12","author":"Striano","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0480","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1517\/14656566.2013.800045","article-title":"Treating myoclonic epilepsy in children: state of the art","volume":"14","author":"Striano","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0485","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/j.1528-1167.2009.02024.x","article-title":"Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis","volume":"50","author":"Tan","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0490","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.18457","article-title":"Homocysteine as a risk factor for atherosclerosis","volume":"34","author":"Temple","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0495","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/0883073808318538","article-title":"Lipid profile, apolipoproteins A and B in children with epilepsy","volume":"23","author":"Tomoum","year":"2008","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0500","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1210\/er.2002-0029","article-title":"Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin","volume":"25","author":"van der Lely","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0505","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.53.1.230","article-title":"Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid","volume":"53","author":"Verrotti","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0510","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0920-1211(00)00150-9","article-title":"Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine","volume":"41","author":"Verrotti","year":"2000","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0515","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/088307380201700405","article-title":"Insulin resistance in epileptic girls who gain weight after therapy with valproic acid","volume":"17","author":"Verrotti","year":"2002","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0520","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000077274","article-title":"Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate","volume":"79","author":"Verrotti","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0525","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","article-title":"The metabolic syndrome in overweight epileptic patients treated with valproic acid","volume":"51","author":"Verrotti","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0530","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eplepsyres.2006.05.002","article-title":"Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monother-apy","volume":"70","author":"Voudris","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0535","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1532-5415.2010.03078.x","article-title":"Prevalence of metabolic syndrome in an elderly Chinese population: a community-based cross-sectional study","volume":"58","author":"Wang","year":"2010","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.eplepsyres.2013.08.016_bib0540","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.braindev.2011.05.009","article-title":"Effects of oxcarbazepine treatment on serum lipids and carotid intima media thickness in children","volume":"34","author":"Yi\u015f","year":"2012","journal-title":"Brain Dev."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:28:52Z","timestamp":1760275732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121113002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":102,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0920121113002210"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.08.016","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic and endocrine effects of valproic acid chronic treatment","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}